Onasemnogene abeparvovec (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Onasemnogene abeparvovec" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

low place

low place

274^th place

596^th place

low place

low place

447^th place

792^nd place

1theguardian.com

12^th place

49^th place

5^th place

7^th place

fda.gov

"FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality". FDA (dalam bahasa Inggris). 2019-05-24. Diakses tanggal 2019-05-24.

novartis.com

"Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1 | Novartis". Novartis (dalam bahasa Inggris). Diakses tanggal 2018-12-04.
"Novartis successfully completes acquisition of AveXis, Inc. | Novartis". Novartis (dalam bahasa Inggris). Diakses tanggal 2018-10-06.

sma-europe.eu

"AveXis receives FDA approval for Zolgensma®, the first gene therapy for paediatric patients with SMA". SMA Europe (dalam bahasa Inggris). 2015-05-25. Diakses tanggal 2019-05-25.

springer.com

adisinsight.springer.com

"Onasemnogene abeparvovec - AveXis - AdisInsight". adisinsight.springer.com (dalam bahasa Inggris). Diakses tanggal 2018-10-06.

theguardian.com

Reuters (2019-05-25). "$2.1m Novartis gene therapy to become world's most expensive drug". The Guardian (dalam bahasa Inggris). ISSN 0261-3077. Diakses tanggal 2019-05-25.

worldcat.org

Reuters (2019-05-25). "$2.1m Novartis gene therapy to become world's most expensive drug". The Guardian (dalam bahasa Inggris). ISSN 0261-3077. Diakses tanggal 2019-05-25.